Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Infectious Diseases: Epidemiology and Prevention
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1357073
This article is part of the Research Topic Public risk perception in public health policies View all 14 articles

Decoding Fujian's Cervical HPV Landscape: Unmasking Dominance of Non-16/18 HR-HPV and Tailoring Prevention Strategies at a Large Scale

Provisionally accepted
Yulong Zhang Yulong Zhang 1Haibo Li Haibo Li 2Qianru You Qianru You 2yusha chen yusha chen 3*Zhiyan Zhao Zhiyan Zhao 4jiancui chen jiancui chen 3*yanzhao su yanzhao su 2*Xiangqin Zheng Xiangqin Zheng 2*huan yi huan yi 2*Jianrong Song Jianrong Song 2*
  • 1 Department of Gynecology, Fujian Women and Children Hospital, Fuzhou, Fujian Province, China
  • 2 Fujian Maternity and Child Health Hospital, Fuzhou, Fujian Province, China
  • 3 Fujian Provincial Cervical Disease Diagnosis and Treatment Health Center, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian Province, China
  • 4 Department of Integrative Biology, College of Letters and Science, University of California, Berkeley, Berkeley, California, United States

The final, formatted version of the article will be published soon.

    Background: Persistent HR-HPV causes cervical cancer, exhibiting geographic variance. Europe/Americas have higher HPV16/18 rates, while Asia/Africa predominantly have non-16/18 HR-HPV. This study in Fujian, Asia, explores non-16/18 HR-HPV infections, assessing their epidemiology and cervical lesion association for targeted prevention. Methods: A total of 101,621 women undergoing HPV screening at a hospital in Fujian Province from 2013-2019 were included. HPV genotyping was performed. A subset of 11,666 HPV-positive women with available histopathology results were analyzed to characterize HPV genotype distribution across cervical diagnoses. Results: In 101,621 samples, 24.5% tested positive for HPV. Among these samples, 17.3% exhibited single infections, while 7.2% showed evidence of multiple infections. The predominant non-16/18 high-risk HPV types identified were HPV 52, 58, 53, 51, and 81. Single HPV infections accounted for 64.1% of all HPV-positive cases, with 71.4% of these being non-16/18 high-risk HPV infections. Age-related variations were observed in 11,666 HPV-positive patients with pathological results. Cancer patients were older. In the cancer group, HPV52 (21.8%) and HPV58 (18.6%) were the predominant types, followed by HPV33, HPV31, and HPV53. Compared to single HPV16/18 infection, non-16/18 HPV predominated in LSIL. Adjusted odds ratios (OR) for LSIL were elevated: multiple HPV16/18 (OR 2.18), multiple non-16/18 HR-HPV (OR 2.53), and multiple LR-HPV (OR 2.38). Notably, solitary HPV16/18 conferred higher odds for HSIL and cancer. Conclusions: Our large-scale analysis in Fujian Province highlights HPV 52, 58, 53, 51, and 81 as predominant non-16/18 HR-HPV types. Multiple HPV poses increased LSIL risks, while solitary HPV16/18 elevates HSIL and cancer odds.These findings stress tailored cervical cancer prevention, highlighting specific HPV impacts on lesion severity and guiding region-specific strategies for optimal screening in Asia, emphasizing ongoing surveillance in the vaccination era.

    Keywords: cervical cancer, Human papillomavirus, Genotype, Prevalence, prevention

    Received: 17 Dec 2023; Accepted: 16 May 2024.

    Copyright: © 2024 Zhang, Li, You, chen, Zhao, chen, su, Zheng, yi and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    yusha chen, Fujian Provincial Cervical Disease Diagnosis and Treatment Health Center, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian Province, China
    jiancui chen, Fujian Provincial Cervical Disease Diagnosis and Treatment Health Center, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian Province, China
    yanzhao su, Fujian Maternity and Child Health Hospital, Fuzhou, 350001, Fujian Province, China
    Xiangqin Zheng, Fujian Maternity and Child Health Hospital, Fuzhou, 350001, Fujian Province, China
    huan yi, Fujian Maternity and Child Health Hospital, Fuzhou, 350001, Fujian Province, China
    Jianrong Song, Fujian Maternity and Child Health Hospital, Fuzhou, 350001, Fujian Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.